Natco Guides FY27 Revenue INR3,400–3,500 Crores Despite Revlimid Drop

Natco Pharma Limited — Q4 FY26 Earnings Conference Call (Quarter ended Mar 31, 2026) | May 29, 2026

1. Overall Tone of Management: Neutral to Optimistic

• Management acknowledges a material earnings decline (“decline… impact on our earnings is substantial” and “drop… by half”).
• However, they balance this with specific growth levers (semaglutide vial/pen performance, Brazil/Canada oncology launches, South Africa associate contribution) and quantified FY27 expectations plus a 15%–25% compounding narrative from FY28.

2. Key Themes from Management Commentary

• Lenalidomide (Revlimid) decline is the main headwind
• Explicitly framed as “earnings without lenalidomide” and “practically no lenalidomide or it’s very competitive.”
• Semaglutide is becoming a diversification “trigger,” especially via vial
• Vial launched first; pen launched later due to logistics; management emphasizes price-sensitive market capture and competitive share gains.
• Geographic diversification strategy is progressing
• Earnings now framed across U.S., Brazil, Canada, India, and South Africa (associate) rather than being U.S.-only.
• South Africa (Adcock Ingram) is positioned as the stability engine
• Management argues it reduces volatility and supports long-term ROI (“15% to 20% return on capital… will take time”).
• R&D and pipeline remain central, but guidance is cautious on “jackpots”
• They avoid naming exclusivities by year due to confidentiality, but still provide a growth framework tied to exclusivity “kicking in” post FY27.
• Cost structure pressure in the quarter
• Higher R&D and engineering write-downs cited as drivers of other expenses.

3. Q&A Analysis

Theme A: Sales decline drivers (Revlimid + geopolitical impact + cost inflation)

• Core questions
• Impact of Revlimid on lower YoY sales; whether West Asia war affected supply/demand.
• Why other expenses rose as % of sales; any one-time items.
• Management response
• Revlimid decline confirmed as primary driver.
• Middle East: “we were able to supply… challenges… but… increase in freight expenses” due to rerouting.
• Other expenses: largely higher R&D plus engineering expense write-downs; quantified at INR20–30 crores for R&D + engineering write-down.
• Assessment
• Direct and quantified answer on expense drivers; geopolitical impact acknowledged but framed as manageable.

Theme B: FY27 guidance / lack of formal “presentation guidance”

• Core questions
• Analyst asked why no guidance in presentation; request for FY27 revenue/PAT.
• Management response
• CEO provided explicit expectations:
  • Revenue: INR3,400–3,500 crores
  • PAT: INR700–750 crores
  • Associate (South Africa) revenue/PAT assumptions also provided (USD $580m–$600m revenue; PAT $47m–$48m), with exchange-rate sensitivity.
• Assessment
• Strongly responsive; however, guidance is still partly assumption-based (“buffer… increase because of the war”).

Theme C: Semaglutide launch performance (India vial vs pen; timing; competitive intensity)

• Core questions
• Whether there was meaningful pomalidomide revenue (timing of booking).
• Semaglutide pen launch visibility; channel strategy (digital platforms).
• Outcome vs initial expectations: market size and Natco share.
• Management response
• Pomalidomide: “I didn’t see a bump… nothing substantial.”
• Semaglutide:
  • Pen not on day 1; launched later; competitive launch.
  • Vial doing better; pen getting some share.
  • Run-rate: brand about INR2 crores/month; partners INR4–5 crores bump in earnings/month (normalized).
  • Annualized expectation: INR75–100 crores.
  • Pen marketing quiet because earlier press announcement covered it; logistics delayed day-1.
• Assessment
• Provides concrete run-rate and annualized revenue expectation—unusually specific for a competitive launch.
• Still admits competitiveness and delayed pen launch (partial weakness).

Theme D: Investor confidence / “what triggers value creation”

• Core questions
• What will improve investor confidence and drive growth next year?
• What gives confidence FY27 is better than FY26?
• Management response
• Triggers: semaglutide, Brazil oncology first-time launches, and South Africa associate income.
• FY27 confidence framed as cyclical business understanding + pipeline exclusivities post FY27.
• Assessment
• Narrative is consistent with prior “jackpot + dip” model, but they now provide more quantified FY27.

Theme E: M&A progress and capital allocation

• Core questions
• Progress on “one more” acquisition after Adcock.
• Whether buybacks are considered given cash.
• Management response
• Transactions “being looked at,” but “nothing… at a stage where I can tell you.”
• Buyback: explicitly rejected—cash should be used for acquisitions (“my personal belief is this cash should be used for an acquisition”).
• Geography preference: “bullish outside India… not bullish in India” (valuations).
• Assessment
• Clear capital allocation stance; but no deal specifics (typical deferral).

Theme F: R&D spend surge and other income

• Core questions
• Why R&D and other expenses jumped QoQ; whether recurring.
• Why other income rose.
• Management response
• R&D timing can’t be controlled; includes inventory write-down of stores/spares and onetime engineering write-down.
• Next year R&D expected 7%–9% (qualitatively “baked into PAT”).
• Other income: interest, PLI, and licensing income (semaglutide India licensing and foreign partner licensing), described as cyclical.
• Assessment
• Reasonably transparent; recurring vs one-time is partially addressed (R&D recurring range given; engineering write-down treated as one-time).

Theme G: Crop Health Sciences / demerger / agri impact from war

• Core questions
• War impact on agrichem business; plant status (FDA facilities).
• Crop division outlook and demerger rationale.
• Management response
• Input raw materials up 25%–30%; inventory mitigates near-term; export less impacted than domestic.
• FDA facilities: 3 cleared with EIRs; Vizag pending inspection expected “any moment.”
• Crop demerger: customers differ; focus on differentiated/patent-controlled products; segment revenue improved from ~INR60 crores to ~INR140 crores; aspirations to grow.
• Assessment
• Provides operational detail (FDA facility list + inspection status).

Theme H: Innovative pipeline (NRC-2694, eGenesis)

• Core questions
• Commercialization timeline for NRC-2694; milestones for eGenesis; when revenue contribution might occur.
• Management response
• NRC-2694: “too early stage.”
• eGenesis: milestones tied to dosing/immunosuppression; expects more transplants in 12–18 months; revenue timing not quantifiable (“binary event”).
• Assessment
• Strong on scientific framing; weak on financial timeline (expected).

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 (management expectation)
• Revenue: INR3,400–3,500 crores
• PAT: INR700–750 crores
• South Africa associate (Adcock) assumptions:
  • Revenue: USD $580m–$600m
  • PAT: USD $47m–$48m
• Tax rate (new regime)
• FY27 tax rate: ~25% including surcharge
• R&D
• Next year R&D expected 7%–9% (as % of revenue; qualitative “baked into PAT”)
• Cash
• Net cash at group level: ~INR2,400 crores
• Semaglutide India
• Annualized expectation: INR75–100 crores (vial-led)
• Earnings growth framework
• CEO expects earnings compounding ~15%–25% every year starting from ’28 (with FY27 as base year around INR700–750 crores)

Implicit signals (qualitative)

• FY27 is a “base year” after lenalidomide decline; upside depends on semaglutide uptake and exclusivity triggers in FY27–FY28.
• No major “named” launches in FY27 (they repeatedly imply pipeline approvals/launches are more meaningful in FY27–FY28).
• M&A remains active but deal timing uncertain; acquisitions prioritized for diversification and stability.
• Volatility acknowledged as structural (“roller coaster ride”), but mitigated via diversification (South Africa + Brazil/Canada).

5. Standout Statements (direct / high-signal)

• On FY27 base and decline:
• “We should do about INR3,400 crores to INR3,500 crores of revenue. Our PAT expectation is between INR700 crores to INR750 crores.”
• “This year… we’re going to drop to about INR700 crores, INR750 crores this year. But things will turn around.”
• On semaglutide performance:
• “The run rate now… INR2 crores a month… partners… INR4 crores to INR5 crores bump in our earnings…”
• “We are thinking that we should be able to do about INR75 crores to INR100 crores annualized.”
• On growth from FY28:
• “earnings should compound around 15% to 25% every year starting from ’28.”
• On volatility and strategy:
• “This is a roller coaster ride…”
• “my personal belief is this cash should be used for an acquisition…”
• On South Africa ROI:
• “return… about 15% to 20% return on capital… it will take time”
• On R&D cadence:
• “You can’t time your R&D expenditure…”
• On acquisitions:
• “We are looking at a couple of transactions… hopefully… achieve something in this financial year” (no specifics)

6. Red Flags / Positive Signals (Optional)

Red flags
– Guidance is assumption-heavy (war/freight, exchange rate for Adcock, competitive semaglutide market).
– No clarity on exclusivity timing beyond broad FY27–FY28 triggers; confidentiality limits transparency.
– M&A remains non-committal (“no update… nothing at a stage where I can tell you”).
– Volatility explicitly admitted; “stable earnings” is a goal, not a proven track record.

Positive signals
– Quantified FY27 revenue/PAT and tax rate.
– Concrete semaglutide run-rate and annualized expectation despite competitive environment.
– R&D spend normalized with a % range (7%–9%)—helps model costs.
– Operational transparency on FDA facility inspection status and crop demerger rationale.

7. Historical Comparison & Consistency Analysis (vs prior calls provided)

a. Change in Tone Over Time

• FY25 Q4 call (May 29, 2025): management guided a possible dip (“dip in revenue by 20% and profits by 30%”) due to U.S. headwinds and Revlimid erosion; tone was cautious but confident in pipeline.
• FY26 Q2 call (Nov 14, 2025): tone leaned more positive on execution (“this quarter we have done extremely well”), but still acknowledged competition and uncertainty; guidance was more about run-rate and budgeting.
• FY26 Q4 call (May 29, 2026): tone is more balanced—they clearly state the decline and “drop by half,” but provide more explicit FY27 numbers and a clear FY28 compounding framework.
• Classification shift: More Optimistic than FY25 Q4 (because they now give quantified FY27 expectations and semaglutide performance metrics), but still not fully confident due to competitive and geopolitical qualifiers.

b. Tracking Past Commitments vs Outcomes

1) Past statement (FY25 Q4, May 29 2025): “possible dip in revenue by 20% and profits by 30%” for FY26.
– Expected: moderate decline.
– What happened (current call): FY26 revenue and PAT materially lower vs FY25:
– FY26 revenue INR4,375.9 cr vs INR4,784 cr
– FY26 PAT INR1,418.5 cr vs INR1,883.4 cr
– Flag: ✅ Directionally consistent (decline occurred), but magnitude appears larger than “30% profit dip” depending on how one compares base vs one-offs; management now frames FY27 PAT as INR700–750 cr (much lower than FY26 PAT), implying the earlier “dip” may have been understated or timing-shifted.
2) Past statement (FY25 Q4, May 29 2025): Agrochem “turn around… hit critical mass… break even this year” (FY26).
– Expected: break-even/turnaround in FY26.
– What happened (current call): Crop division is still discussed as needing focus; management highlights demerger and growth aspirations, but no claim of break-even in FY26 within this transcript.
– Flag: ⏳ Delayed / not clearly delivered (no explicit break-even confirmation in FY26 Q4 call).
3) Past statement (FY25 Q4, May 29 2025): acquisitions “positive that we’ll be able to close something in this financial year.”
– Expected: at least one acquisition in FY26.
– What happened (current call): Adcock Ingram acquisition already completed (South Africa associate contribution now central).
– Flag: ✅ Delivered (Adcock investment is the major outcome).

c. Narrative Shifts

• From U.S.-centric volatility to multi-market diversification
• Earlier calls emphasized U.S. headwinds and Revlimid erosion.
• Current call emphasizes Brazil/Canada oncology + South Africa associate as stability levers.
• Semaglutide narrative matured
• FY25 call: semaglutide expected around first wave (more conditional).
• FY26 call: semaglutide now has run-rate, annualized expectation, and competitive share commentary.
• Crop Health Sciences moved toward structural separation
• Current call: demerger rationale and segment revenue trajectory; earlier calls treated agro as a turnaround story.

d. Consistency & Credibility Signals

• Credibility: Medium
• Positives: management provides more quantified guidance now (FY27 revenue/PAT, semaglutide annualized, R&D %).
• Concerns: recurring pattern of “cyclical/one-offs/jackpots” with limited ability to name exclusivities by year; also some earlier turnaround expectations (Agro) are not clearly evidenced as achieved in the current transcript.

e. Evolution of Key Themes

• Demand / competition: Deterioration acknowledged for Revlimid; semaglutide described as “very competitive.”
• Margins: Still framed as volatile; management expects contraction in FY26 and aims for stability via diversification.
• Expansion: Continued emphasis on Brazil/Canada and South Africa; U.S. remains important but not the sole driver.
• Regulatory / pipeline: More filings discussed (7–8 in U.S. last year; 8–9 targeted next), but exclusivity timing remains confidential.

f. Additional Insights (Cross-Period Intelligence)

• The company’s “stability” thesis increasingly relies on associate earnings (Adcock) and non-U.S. oncology launches, suggesting that U.S. base profitability alone is insufficient to smooth volatility.
• Management’s repeated “roller coaster ride” framing suggests they view volatility as structural; the “stable earnings” goal is being pursued via diversification rather than by eliminating the core cyclicality.